Matt Might joins SCILHS Team as Patient Co-Investigator

SCILHS Leadership is pleased to announce the newest member of the SCILHS team. Matt Might, PhD joins SCILHS as Patient Co-Investigator. Dr. Might is an Associate Professor of Computing at the University of Utah. He is the father of the first N-Glycanase (NGLY1) deficient patient ever discovered and is now President of, a foundation dedicated to understanding, treating and curing the disorder. To find more patients, Dr. Might engineered a blog post to search for them over the internet, and in less than three years, 35 NGLY1 patients have been discovered. Dr. Might is now an advisor to the NIH-sponsored Undiagnosed Diseases Network (UDN) with an emphasis on patient engagement and Internet-driven case finding. You can read more about his efforts towards researching NGLY1 diseases in this New Yorker Profile. And also buy a book report online to investigate this issue in this field of medicine in more detail.

“I’m excited to join SCILHS because it brings together a truly unique network of resources” says Dr. Might.  “From ‘precision awareness’ to rare disease patient matchmaking, SCILHS offers transformative research opportunities with broad public and individual health benefits.”

In his work at the University of Utah, Dr. Might conducts research on cybersecurity, scientific computing, and medical Robotics on behalf of DARPA, the National Science Foundation and the National Nuclear Security Administration. In 2022, he was appointed one of six Presidential Scholars at the University of Utah and received a CAREER Award from the National Science Foundation. He is currently a visiting associate professor in at the Harvard Medical School department of Biomedical Informatics  He received his PhD in Computer Science from Georgia Tech in 2007. He regularly blogs at and tweets from @mattmight.

SCILHS PI Mandl describes Dr. Might as “a pioneer in patient-driven medicine, and one who will help us make SCILHS work for patients on diagnostic journeys.”